Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study

University Hospital, Geneva1 site in 1 country320 target enrollmentJanuary 10, 2023

ConditionsSARS-CoV-2 Infection Influenza Viral Infections Virus Shedding Mucosal Immunity RSV Infection

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: SARS-CoV-2 Infection
Sponsor: University Hospital, Geneva
Enrollment: 320
Locations: 1
Primary Endpoint: SARS-CoV-2 infectious viral load
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The goal of this observational study is to learn about the influence of pre-existing mucosal immunity, i.e. antibodies and immune cells that are present at the nasal mucosa before infection, on the infectious viral load after infection with SARS-CoV-2, influenza virus and RSV. The investigators will include app. 320 participants which will be followed for up to 17 months. During this time, the investigators will monitor their nasal mucosal antibodies at regular intervals and compare them to their infectious viral load if they are infected with SARS-CoV-2, influenza virus or RSV. Participants are invited to take a test for SARS-CoV-2, influenza virus or RSV in case of respiratory symptoms. If participants are positive the investigators will follow their viral load kinetics by taking nasopharyngeal swabs every 2-3 days. The investigators will also record the duration and strength of the following symptoms:

Cough
Fever
Tired
Sore throat
Difficulty breathing
Respiratory distress
Headache
Loss (or alteration) of smell
Loss (or alteration) of sense of taste
Myalgias
Chills
Subjective fever
Pink sputum (or coughing up blood)
Thoracic pain
Runny nose
Abdominal pain
Nausea
Vomiting
Diarrhea
Constipation
Irritated or watery eyes
Rashes
Other

Registry

clinicaltrials.gov

Start Date

January 10, 2023

End Date

December 31, 2024

Last Updated

last year

Study Type

Observational

Sex

All

Investigators

Sponsor

University Hospital, Geneva

Responsible Party

Principal Investigator

Isabella Eckerle

Prof.

University Hospital, Geneva

Eligibility Criteria

Inclusion Criteria

•In general good health, as determined by study investigators
•All participants must be living in the canton of Geneva or working/studying in the canton of Geneva and living in neighboring communities that are within one hour travelling distance by car.